NACDS continues to urge collaboration across the Biden Administration and the U.S. Congress to help ensure allocation of funding for the Health Resources and Services Administration (HRSA) Uninsured Program, Coverage Assistance Fund (CAF) Program, testing programs and other essential COVID-19 care programs for COVID-19 vaccinations, testing and treatment.
NACDS President and CEO Steven C. Anderson issued the following statement today related to the introduction of bipartisan legislation in the U.S. House of Representatives that would help ensure the continuity of accessible pharmacy-based care:
Especially for the most vulnerable Americans, the CDC article emphasized the critical importance of sustained pharmacy access.
NACDS urges Biden Administration to ensure clarity or to act decisively to extend PREP Act authorities that have served Americans well, and that Americans do not want to see rolled back.
NACDS comment letter to Biden Administration urges CMS to finalize proposal, implement regulatory guardrails and standardized pharmacy measures that best serve Medicare patients and help protect pharmacy viability.
NACDS President and CEO Steven C. Anderson issued the following statement today following statements by the American Medical Association (AMA) regarding the Test to Treat Initiative for COVID antivirals that was mentioned by President Joe Biden and released by the Biden Administration last week.
On Wednesday, March 2, the Oversight and Investigations Subcommittee of the U.S. House of Representatives Energy and Commerce Committee held a hearing titled, “Lessons from the Frontline: COVID-19’s Impact on American Health Care.”
During the State of the Union address on March 1, 2022, President Biden discussed the launch of the Test-to-Treat Iniative for COVID-19 antivirals.
U.S. House Energy and Commerce subcommittee to hold hearing on pandemic’s lessons.
Morning Consult conducted the survey of U.S. adults, which was commissioned by NACDS, from February 15-16.
